论文信息 - Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC. - 字舞流文

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

M. Tiseo | A. Leonetti | C. Lagrasta | L. Bottarelli | C. Azzoni | P. Petronini | R. Alfieri | L. Gnetti | N. Campanini | S. La Monica | P. Bordi | R. Minari | A. Squadrilli